

Substitute for form 1449B/PTO

**FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**

LISTING OF REFERENCES

SEPTEMBER 4, 2007

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
2907.1000-003

APPLICATION NO.
10/686,943

FIRST NAMED INVENTOR
Andrew McMichael

FILING DATE
October 16, 2003

EXAMINER
Louise Humphrey,
Ph.D.

CONFIRMATION NO.
4585

GROUP
1648

U.S. PATENT DOCUMENTS

EXAM- INER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
/L.H./	A6	2004/0018177 A1	01-29-2004	Hill, <i>et al.</i>

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
/L.H./	B11	WO 02/068654 A3	09-06-2002	Centro de Ingenieria Genetica y Biotecnologia	
/L.H./	B12	WO 2005/030964 A1	04-07-2005	Oxxon Therapeutics Limited	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/L.H./	C63	"AIDS Vaccines Trials Dangerous," Isis News No. 11/12, Ho, M., ed., <i>Institute of Science in Society</i> [online], October 2001. Retrieved from the Internet, [retrieved on 2006].
	C64	Altman, J.D., and Feinberg, M.B., "HIV Escape: There and Back Again," <i>Nature Med.</i> 10(3): 229-230 (2004).
	C65	Borrow, P., <i>et al.</i> , "Virus-Specific CD8 ⁺ Cytotoxic T-Lymphocyte Activity Associated with Control of Viremia in Primary Human Immunodeficiency Virus Type 1 Infection," <i>J. Virology</i> 68(9): 6103-6110 (1994).
	C66	Brander, C. and Walker, B.D., The HLA Class I Restricted CTL Response in HIV-1 Infection: Systematic Identification of Optimal Epitopes. HIV Molecular Immunology Database [online], February 2002 [retrieved on 2006-10-19], Retrieved from the Internet <URL:http://www.hiv-web.lanl.gov>.
	C67	Desrosiers, R.C., "Prospects for an AIDS Vaccine," <i>Nature Med.</i> 10(3):221-223 (2004).
	C68	Dose-Ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers [online], February 2007 [retrieved on 2007-03-07], Retrieved from the Internet <URL:http://www.clinicaltrials.gov>.
	C69	Fang, Z.-Y., <i>et al.</i> , "Expression of Vaccinia E3L and K3L Genes by a Novel Recombinant Canarypox HIV Vaccine Vector Enhances HIV-1 Pseudovirion Production and Inhibits Apoptosis in Human Cells," <i>Virology</i> 291:272-284 (2001).
✓	C70	Friedrich, T.C., <i>et al.</i> , "Reversion of CTL Escape - Variant Immunodeficiency Viruses <i>in vivo</i> ," <i>Nature Med.</i> 10(3):275-281 (2004).

EXAMINER

/Louise Humphrey/

DATE CONSIDERED

10/31/2007

Substitute for form 1449B/PTO FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES SEPTEMBER 4, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003		APPLICATION NO. 10/686,943	
	FIRST NAMED INVENTOR Andrew McMichael		FILING DATE October 16, 2003	
	EXAMINER Louise Humphrey, Ph.D.	CONFIRMATION NO. 4585	GROUP 1648	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/L.H./	C71	Hu, S.-L., "Non-Human Primate Models for AIDS Vaccine Research," <i>Curr. Drug Targets Infect. Disord.</i> , 5(2):193-201 (2005).
	C72	Huygen, K., <i>et al.</i> , "Immunogenicity and Protective Efficacy of a Tuberculosis DNA Vaccine," <i>Nature Med.</i> 2(8): 893-898 (1996).
	C73	Kmiecniak, D., <i>et al.</i> , "Enhancement of Cellular and Humoral Immune Responses to Human Immunodeficiency Virus Type 1 Gag and Pol by a G/P-92 Fusion Protein Expressing Highly Immunogenic Gag p17/p24 and Pol p51 Antigens," <i>J. Hum. Virol.</i> 4(6):306-316(2001).
	C74	Koziel, M.J., "The Role of Immune Responses in the Pathogenesis of Hepatitis C Virus Infection," <i>J. Viral Hepatitis</i> 4(2):31-41 (1997).
	C75	Koziel, M.J. and Walker, B.D., "Characteristics of the Intrahepatic Cytotoxic T Lymphocyte Response in Chronic Hepatitis C Virus Infection," <i>Spriner Seminars in Immunopathology</i> , 19(1):69-83 (1997).
	C76	Leslie, A.J., <i>et al.</i> , "HIV Evolution: CTL Escape Mutation and Reversion After Transmission," <i>Nature Med.</i> 10(3):282-289 (2004).
	C77	Letvin, N.L., "Progress Toward an HIV Vaccine," <i>Annu. Rev. Med.</i> 56:213-223 (2005).
	C78	Matano, T., <i>et al.</i> , "Administration of an Anti-CD8 Monoclonal Antibody Interferes with the Clearance of Chimeric Simian/Human Immunodeficiency Virus during Primary Infections of Rhesus Macaques," <i>J. Virology</i> 72(1): 164-169 (1998).
	C79	Picard, O., <i>et al.</i> , "Complication of Intramuscular/Subcutaneous Immune Therapy in Severely Immune-compromised Individuals," <i>J. Acquir. Immune Defic. Syndr.</i> , 4(6):641-643 (1991).
	C80	Puig, M., <i>et al.</i> , "CD4+ Immune Escape and Subsequent T-Cell Failure Following Chimpanzee Immunization Against Hepatitis C Virus," <i>Hepatology</i> , 44:736-745 (2006).
	C81	Puls, R.L. and Emery, S., "Therapeutic Vaccination against HIV: Current Progress and Future Possibilities," <i>Clin. Sci.</i> , 110(1):59-71 (2006).
	C82	Riddell, S.R. and Greenberg, P.D., "Principles for Adoptive T Cell Therapy of Human Viral Diseases," <i>Annu. Rev. Immunol.</i> 13: 545-586 (1995).
	C83	Riddell, S.R., <i>et al.</i> "Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones," <i>Science</i> 257 (1992).
	C84	Rowland-Jones, S., <i>et al.</i> , "HIV-specific Cytotoxic T-cells in HIV-exposed but Uninfected Gambian Women," <i>Nature Medicine</i> 1(1): 59-64 (1995).
↓	C85	Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults. National Institute of Allergy and Infectious Diseases [online], September 2006 [retrieved on 2007-03-07], Retrieved from the Internet <URL:http://www.clinicaltrials.gov>.

EXAMINER /Louise Humphrey/	DATE CONSIDERED 10/31/2007
-------------------------------	-------------------------------

Substitute for form 1449B/PTO FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES SEPTEMBER 4, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003		APPLICATION NO. 10/686,943	
	FIRST NAMED INVENTOR Andrew McMichael		FILING DATE October 16, 2003	
	EXAMINER Louise Humphrey, Ph.D.	CONFIRMATION NO. 4585	GROUP 1648	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/L.H./	C86	Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vector HIV Vaccine in Healthy Adults. National Institute of Allergy and Infectious Diseases [online], January 2007 [retrieved on 2007-03-01], Retrieved from the Internet <URL:http://www.clinicaltrials.gov>.
/L.H./	C87	Smith, C.L., <i>et al.</i> , "Recombinant Modified Vaccinia Ankara Primes Functionally Activated CTL Specific for a Melanoma Tumor Antigen Epitope in Melanoma Patients with a High Risk of Disease Recurrence," <i>Int. J. Cancer</i> 113:259-266 (2005).
/L.H./	C88	Tonini, T., <i>et al.</i> , "Current Approaches to Developing a Preventative HIV Vaccine," <i>Curr. Opin. Investig. Drugs</i> , 6(2):155-162 (2005).
/L.H./	C89	Wiley, J.A., <i>et al.</i> , "Production of Interferon- γ by Influenza Hemagglutinin-Specific CD8 Effector T Cells Influences the Development of Pulmonary Immunopathology," <i>Am. J. Pathol.</i> 158(1): 119-130 (2001).

EXAMINER /Louise Humphrey/	DATE CONSIDERED 10/31/2007
-----------------------------------	-----------------------------------